Commercialising the science of the Babraham Institute



The Babraham Institute aims to maximise the impact of its research through knowledge exchange and commercialisation, and our scientists work with other organisations to translate that research into action for social and economic benefit. Commercialisation is achieved in collaboration with the Institute’s wholly-owned trading arm, Babraham Institute Enterprise Limited.

Babraham Institute Enterprise is situated in the Babraham Research Campus.  The Campus, which is considered to be the UK’s leading campus in supporting early-stage bioscience enterprise, is managed and developed Babraham Bioscience Technologies Ltd (BBT).

The Campus' bioincubator concept offers bespoke, state-of-the-art research and development facilities, scientific support services and/or bioventures at any stage in the business development cycle and supports the full spectrum of science from R&D to commercial realisation.

B930 Opening

Babraham Institute Enterprise (BIE) supports the delivery of the commercialisation of the Babraham Institute’s science through the following mechanisms:
  • Managing and commercialising the Institute’s intellectual property, including through licensing to companies.
  • Facilitating collaborations between the Institute’s scientists and industry.
  • Arranging access to the Institute’s scientific expertise and facilities.
BIE and the Institute currently work with over 80 industry partners including both large pharmaceutical companies and smaller and medium sized biotechs, many of which are located on the Babraham Research Campus

We are always aiming to further our collaborations with industry, and with this purpose in mind, arrange a number of networking events for both Institute and commercial scientists.


A report into the impact of the Babraham Institute, carried out by Alacrita LLP, has concluded that it makes major economic impacts through its world-class research. In addition to the Institute’s academic impact, it has made major scientific contributions to the commercial development of therapeutics in several key areas, for example the development of humanised monoclonal antibodies and PI3 Kinase inhibitors.

Staff and Board Members

Katherine Montague

Commercialisation Manager

David Brown

BIE Board Member

Michael Wakelam

Director of Institute

Alan Watt

BIE Board Member

Page: Notes